BlinkLab Limited (ASX:BB1) Reports Early Genetic Autism Study Results as Screening Work Expands

Aditi Sarkar

11 November 2026 04:33 PM AEDT

BlinkLab Limited (ASX:BB1) Reports Early Genetic Autism Study Results as Screening Work Expands

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• BlinkLab announced positive genetic autism study results ahead of schedule in a market-sensitive November release.

• The company had announced nationwide autism screening activity in Morocco during October 2026 as part of its development programme.

• BlinkLab reported FY26 Revenue of approximately AUD 1.21 million, up from AUD 0.38 million in FY25.

• Shares advanced around 4.82% intraday on 11 November, with trading Volume near twice the daily average.

Genetic autism research took centre stage for BlinkLab Limited (ASX:BB1) on 11 November 2026. A price-sensitive announcement reported positive study results ahead of schedule, adding to the company’s recent updates about autism screening activity and technology development.

Market Setting

BlinkLab Limited was higher on Wednesday, with the shares up 4.82% at 59.8 cents at around 2:40pm AEDT on 11 November 2026. About 408,000 shares had traded, roughly double the stock’s Average Daily Volume of about 200,000 on ASX data.

The announcement came after a Trading halt lodged around 9:28am on 9 November, also price-sensitive, which suggests the company was preparing a market-sensitive release. The halt reason could not be verified.

Other recent releases include the quarterly activities and Cash Flow report (about 29 October), the “Commencement of Nationwide Autism Screening in Morocco” (about 22 October), and a presentation to the Simons Foundation and ThinkEquity in New York (announced about 13 October).

Business and Operations

The ASX describes BlinkLab only as a technology company. The company listed in April 2024 and has about 176.3 million shares on issue, giving a Market Value of roughly AUD 100.5 million at the live price.

Financial Performance

ASX data for the year to 30 June 2026 show revenue of about AUD 1.21 million, up from about AUD 0.38 million a year earlier, and a net loss of about AUD 7.2 million, compared with about AUD 5.7 million in 2025. Total Assets were about AUD 20.6 million against liabilities of about AUD 1.1 million.

The shares have traded between 56 cents and AUD 1.105 over 52 weeks, so the stock is still well below its high.

Key Operating Considerations

BlinkLab is loss-making and still building revenue. Results from one study do not equal regulatory clearance or commercial adoption, and the company’s cash needs were not assessed here.

FAQs

Q: When did BlinkLab announce the genetic autism study results?

A: 11 November 2026.

Q: What was the earlier international screening announcement?

A: Commencement of nationwide autism screening in Morocco.

Q: How much FY26 revenue did BlinkLab report?

A: Approximately AUD 1.21 million.

Q: Were study participant numbers provided?

A: Not in the available article information.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.